ABG-WTT Global Life Science Capital Partners GP Ltd

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), ABG-WTT Global Life Science Capital Partners GP Ltd reported 3 stock positions worth $41.5 million. Its top holding was CG Oncology (CGON) at 96.8% of the portfolio, followed by Rapid Micro Biosystems Class A (RPID, 1.9%) and Pulmonx (LUNG, 1.3%). Compared with Q4 2023, it opened 1 new position and sold out of 2. The biggest buy was a new position in CG Oncology (CGON) and the biggest sale an exit from Rayzebio (RYZB).

Most Recent 13F
Q2 2026
Location
CENTRAL, HONG KONG, K3
CIK
0001832108
Portfolio Value
$41.5M (Q1 2024)
SEC Filing
0000950123-24-005234 ↗ filed May 15, 2024

Holdings Value

0$10.0M$20.0M$30.0M$40.0M$50.0M Q1 2024: $41.5M $41.5M Q1 2024 Q2 2024: $30.0M Q2 2024 Q3 2024: $20.1M Q3 2024 Q4 2024: $43.7M Q4 2024 Q1 2025: $38.3M Q1 2025 Q2 2025: $26.8M Q2 2025 Q3 2025: $18.7M Q3 2025 Q4 2025: $15.0M Q4 2025 Q1 2026: $12.3M Q1 2026 Q2 2026: $8.6M Q2 2026

Holdings 3 stocks · $41.5M
CGON CG Oncology Inc. 96.81% 915,501 $40.2M New
RPID Rapid Micro Biosystems Inc. Class A 1.85% 1,038,296 $768K No change
LUNG Pulmonx Corp. 1.34% 60,204 $558K No change

Portfolio Sells Q4 2023 → Q1 2024
RYZB Rayzebio Inc. Sold out 0.00% −94.38
MDVLQ Medavail Holdings Inc. Sold out 0.00% −2.63

Portfolio Buys Q4 2023 → Q1 2024
CGON CG Oncology Inc. New 96.81% +96.81

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$8.6MCBLL, RPID
Q1 2026 2$12.3MCBLL, RPID
Q4 2025 2$15.0MCBLL, RPID
Q3 2025 2$18.7MCBLL, RPID
Q2 2025 2$26.8MCBLL, RPID
Q1 2025 4$38.3MCBLL, CGON, RPID, LUNG
Q4 2024 4$43.7MCBLL, CGON, RPID, LUNG
Q3 2024 3$20.1MCGON, RPID, LUNG
Q2 2024 3$30.0MCGON, RPID, LUNG
Q1 2024 3$41.5MCGON, RPID, LUNG